Inhibition of ERK Signaling for Treatment of ERRα Positive TNBC

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 May 10

PMID 37163498

Authors

David Musheyev

Esther Miller

Natania Birnbaum

Elisheva Miller

Shoshana Erblich

Alyssa Schuck

Anya Alayev

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the second leading cause of cancer-related deaths in women and triple-negative breast cancer (TNBC), in particular, is an aggressive and highly metastatic type of breast cancer that does not respond to established targeted therapies and is associated with poor prognosis and worse survival. Previous studies identified a subgroup of triple-negative breast cancer patients with high expression of estrogen related receptor alpha (ERRα) that has better prognosis when treated with tamoxifen. We therefore set out to identify common targets of tamoxifen and ERRα in the context of TNBC using phosphoproteomic analysis. In this study, we discovered that phosphorylation of mitogen-activated protein kinase 1 (MAPK1) is regulated by tamoxifen as well as ERRα. Additionally, we showed that inhibition of MAPK signaling together with the use of a selective ERRα inverse agonist, XCT-790, leads to a significant upregulation of apoptosis and paves way for the therapeutic use of MAPK inhibitors for treatment of ERRα expressing TNBC.

References

Alayev A, Holz M . mTOR signaling for biological control and cancer. J Cell Physiol. 2013; 228(8):1658-64. PMC: 4491917. DOI: 10.1002/jcp.24351. View

Ariazi E, Clark G, Mertz J . Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res. 2002; 62(22):6510-8. View

Maurer G, Tarkowski B, Baccarini M . Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. 2011; 30(32):3477-88. DOI: 10.1038/onc.2011.160. View

Huss J, Garbacz W, Xie W . Constitutive activities of estrogen-related receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim Biophys Acta. 2015; 1852(9):1912-27. DOI: 10.1016/j.bbadis.2015.06.016. View

Nagini S . Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2016; 17(2):152-163. DOI: 10.2174/1871520616666160502122724. View

Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J . Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12(5):R68. PMC: 3096954. DOI: 10.1186/bcr2635. View

Deblois G, Hall J, Perry M, Laganiere J, Ghahremani M, Park M . Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res. 2009; 69(15):6149-57. DOI: 10.1158/0008-5472.CAN-09-1251. View

Bianco S, Sailland J, Vanacker J . ERRs and cancers: effects on metabolism and on proliferation and migration capacities. J Steroid Biochem Mol Biol. 2011; 130(3-5):180-5. DOI: 10.1016/j.jsbmb.2011.03.014. View

Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L . A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers (Basel). 2019; 11(10). PMC: 6827047. DOI: 10.3390/cancers11101618. View

10.

Herynk M, Fuqua S . Estrogen receptor mutations in human disease. Endocr Rev. 2004; 25(6):869-98. DOI: 10.1210/er.2003-0010. View

11.

Hoeflich K, OBrien C, Boyd Z, Cavet G, Guerrero S, Jung K . In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009; 15(14):4649-64. DOI: 10.1158/1078-0432.CCR-09-0317. View

12.

Zhou S, Xia H, Xu H, Tang Q, Nie Y, Gong Q . ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells. J Exp Clin Cancer Res. 2018; 37(1):218. PMC: 6125878. DOI: 10.1186/s13046-018-0862-8. View

13.

Fuqua S, Chamness G, McGuire W . Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993; 51(2):135-9. DOI: 10.1002/jcb.240510204. View

14.

Berman A, Manna S, Schwartz N, Katz Y, Sun Y, Behrmann C . ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal Transduct Target Ther. 2017; 2. PMC: 5589335. DOI: 10.1038/sigtrans.2017.35. View

15.

Pfeiffer R, Webb-Vargas Y, Wheeler W, Gail M . Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions. Cancer Epidemiol Biomarkers Prev. 2018; 27(10):1214-1222. PMC: 8423092. DOI: 10.1158/1055-9965.EPI-18-0098. View

16.

Nabholtz J, Chalabi N, Radosevic-Robin N, Dauplat M, Mouret-Reynier M, Van Praagh I . Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Int J Cancer. 2015; 138(9):2274-80. DOI: 10.1002/ijc.29952. View

17.

Osborne C, Yochmowitz M, Knight 3rd W, McGuire W . The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980; 46(12 Suppl):2884-8. DOI: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. View

18.

Osborne C . Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339(22):1609-18. DOI: 10.1056/NEJM199811263392207. View

19.

Mayer E, Burstein H . Chemotherapy for Triple-Negative Breast Cancer: Is More Better?. J Clin Oncol. 2016; 34(28):3369-71. DOI: 10.1200/JCO.2016.68.4068. View

20.

De Marchi T, Foekens J, Umar A, Martens J . Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016; 21(7):1181-8. DOI: 10.1016/j.drudis.2016.05.012. View